<DOC>
	<DOC>NCT00252785</DOC>
	<brief_summary>The primary objective of this study is to confirm the efficacy (superiority) of Symbicort® Turbuhaler® 160/4.5 µg twice daily for 8 weeks in comparison to Pulmicort® Turbuhaler® 200 µg twice daily + Theolong® tablet 200 mg twice daily.</brief_summary>
	<brief_title>Efficacy &amp; Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily &amp; Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Diagnosis of asthma with a documented history of at least 6 months duration prior to Visit 1 Prescribed daily use of an IGCS for &gt;=12 weeks prior to Visit 1. The dose of IGCS must be 400 to 800 µg/day of Pulmicort® Turbuhaler® or corresponding dose of IGCS. The prescribed dose of IGCS should be constant for at least 4 weeks prior to Visit 1 Prescribed daily use of sustained release theophylline for at least 8 weeks prior to Visit 1, or confirmed steadystate blood theophylline concentrations within the effective range (515 µg/mL) during 8 weeks prior to Visit 1. The prescribed dose of theophylline should be constant (400 mg/day) for at least 4 weeks prior to Visit 1 Any significant disease or disorder that may jeopardize the safety of the patient Respiratory infection, judged by the investigator(s) as an infection affecting the asthma, within 4 weeks prior to Visit 1 Treatment with oral, parenteral or rectal GCS within 4 weeks prior to Visit 1 Additional inclusion and exclusion criteria will be evaluated by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Asthma</keyword>
</DOC>